Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 5/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27669802 | 1.00 | PDK1 (0.66) | PDK1HTR2AHTR2CHRH1SMN1; SMN2 | |
| SCHEMBL3516619 | 1.00 | PDK1 (0.66) | PDK1HTR2AHTR2CHRH1SMN1; SMN2 | |
| SCHEMBL29580264 | 0.88 | PDK1 (0.53) | PDK1 | |
| SCHEMBL18546470 | 0.88 | PDK1 (0.53) | PDK1 | |
| SCHEMBL27595538 | 0.84 | PDK1 (0.62) | PDK1HTR2AHTR2CHRH1 | |
| SCHEMBL1119076 | 0.84 | PDK1 (0.62) | PDK1HTR2AHTR2CHRH1SMN1; SMN2 | |
| SCHEMBL27172500 | 0.84 | PDK1 (0.62) | PDK1HTR2AHTR2CHRH1SMN1; SMN2 | |
| SCHEMBL26127911 | 0.84 | PDK1 (0.49) | PDK1SMN1; SMN2 | |
| SCHEMBL14167553 | 0.84 | PDK1 (0.49) | PDK1SMN1; SMN2 | |
| SCHEMBL15321980 | 0.81 | PDK1 (0.46) | PDK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109032-B | Quinoline derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-115109032-A | Quinoline derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-104640847-B | Novel Renin Inhibitors | 上海医药集团股份有限公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-109562113-A | Spirocyclo-rongeur for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1620109-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1611127-A2 | 4-SUBSTITUED QUINOLEIN DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| CN-1662498-A | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-31 | — | — | CN | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096234-A2 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
| WO-2004087647-A2 | 4-SUBSTITUTED QUINOLEIN DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1318988-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | Sepracor, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | HRH2, HRH1, HRH3 | PDK1 2699/4885HTR2A 736/4885HTR2C 199/4885 |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | PDK1 387/4885HTR2A 4706/4885HTR2C 4703/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PDK1 988/4885HTR2A 4056/4885HTR2C 4406/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | PDK1 387/4885HTR2A 4706/4885HTR2C 4703/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | PDK1 988/4885HTR2A 4056/4885HTR2C 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.